Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

What really happens after you hit enter on that AI prompt? WSJ’s Joanna Stern heads inside a data center to trace the journey and then grills up some steaks to show just how much energy it takes to ...

[Maximilian Milovidov is a freshman at Columbia University and a member of TikTok's Youth Council. He used a large language model to edit this essay for length and a human to edit for content. This ...

A new study finds that certain patterns of AI use are driving cognitive fatigue, while others can help reduce burnout. by Julie Bedard, Matthew Kropp, Megan Hsu, Olivia T. Karaman, Jason Hawes and ...

Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Dany Lepage discusses the architectural ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...